Associated Papers
Case Report: Clinical benefit from multi-target tyrosine kinase inhibitor and PARP inhibitor in a patient with cancer of unknown primary with BRCA1 large genomic rearrangement.
Yu L et al.
Frontiers in Pharmacology, 2023
Select a paper to view details